MOH Earnings

MOH reported its FY2025Q4 earnings on 2026-02-05, showcasing a revenue of 0.00 against an estimate of 11.00B, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.43 by 0% . The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following MOH's FY2025Q4 earnings announcement on 2026-02-05, the stock price moved by % on the day of the release. Over the subsequent five days, it saw a % change. Historically, MOH's stock price tends to shift by an average of +5.36% in the 10 days leading up to earnings and -1.00% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate MOH’s annual revenue to reach 11.00B, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.41% and EPS estimates Revise Downward by -0.17% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between MOH's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 0.41%, while EPS estimates moved Revise Downward by -0.17% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MOH's stock price typically moves by +5.36% in the 10 days before its earnings and -1.00% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 11.00B.

The earnings call summary reflects challenges in financial guidance with a reduction in EPS and increased MCR, indicating higher costs. While the revenue guidance remains unchanged, the company's competitive position is weak, and Medicaid enrollment is declining. The Q&A session reveals concerns about medical cost trends and potential downside risks. Despite some optimism in Medicaid rate adjustments and M&A opportunities, the overall sentiment suggests a negative outlook due to financial pressures and uncertainties, leading to a predicted stock price decrease of -2% to -8% over the next two weeks.